Professor Hui-Chu Lang



Contact number:(02) 2826-7015

Fax telephone:(02) 2823-7298


● For more info, click here


美國約翰霍普金斯大學 醫療管理博士

國立陽明大學 公共衛生碩士

中國醫藥大學 公共衛生學士


○ 國立陽明大學醫學院醫務管理所專任教授

○ 國立陽明大學醫學院醫務管理所專任副教授

○ 國立陽明大學醫學院醫務管理所專任助理教授


醫務管理研究法、醫療決策分析 、醫療科技評估、醫務管理專題討論

Research interest

o   醫務管理研究法

o   醫療決策分析

o   醫療科技評估

o   醫務管理專題討論

Books (or research publications)

○ 代表著作

1. Yang CP, Cheng HM, LuMC, Lang HC*. Association between continuity of care and survival in Taiwanese stroke patients: a 9-year cohort study. PLos One. 2019 May 22; 14(5):ee0216495. doi: 10.1371/journal.pone. 0216495. eCollection 2019.  MOST 105-2410-H-010 -012 -SS2

2. Cheng HM, Chiou LJ, Chen TC, Sung SH, Chen CH, Lang HC*. Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease-A five-year follow-up study. Health Policy. 2019 Feb;123(2):229-234. doi: 10.1016/j.healthpol.2018.11.010. Epub 2018 Nov 28.  NSC 101-2410-H-010

3. Hsu CS, Lang HC, Huang KY, Chao YC, Chen CL. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.  Hepatol Int. 2018 Nov;12(6):531-543. doi: 10.1007/s12072-018-9905-7. Epub 2018 Nov 14. PMID: 30426396.

4.蔣靜怡,郎慧珠.台灣診所之歇業與存活研究及其相關因素探討─以2000年至2010年新設西醫診所研究為例.台灣衛誌 2017年12月的第36卷第6期.

5.Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, Lu CL. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study. Hepatology. 2017 Sep;66(3):896-907. doi: 10.1002/hep.29172. Epub 2017 May 8.  NSC 101-2410-H-010

6. Sung SH, Chen TC, Cheng HM, Lee JC, Lang HC*, Chen CH*. Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiol Sin. 2017 Jan;33(1):10-19.

7.Chiu YM, Chuang MT, Lang HC. Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study. Rheumatol Int. 2016 Nov;36(11):1507-1514. Epub 2016 Aug 17.

8.Lang HC, Chen HW, Chiou TJ, Chan AL. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016 Oct; 19(10); 923-7.

9.Hsu CS, Lang HC, Huang KY, Lin HH, and Chen CL. Association of Rheumatoid Arthritis and Hepatitis B infection: a Nationwide Nested Case-Control Study from 1999 to 2009 in Taiwan. Medicine(Baltimore). 2016 May;95(18):e3551.

10.Lang HC, Lee HC, Lee SS, Lin HY,Chiu YM,. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: A population based trend study. International Journal of Rheumatic Diseases. Int J Rheum Dis.. 2016 Nov. 19(11): 1112-1118.doi: 10.1111/1756-185X.12813. Epub 2016 Feb 18.

11. Chen SF, Wang IJ, Lang HC*. Risk of major depression in patients with chronic renal failure on different treatment modalities: A matched-cohort and population-based study in Taiwan. Hemodial Int. 2016 Jan;20(1):98-105. doi: 10.1111/hdi.12334. Epub 2015 Jul 14.

12.Cheng JS, Tsai WC, Lin CL, Chen L, Lang HC, Hsieh HM, Shin SJ, Chen T, Huang CT, Hsu CC. Trend and factors associated with healthcare use and costs in type 2 diabetes mellitus: A decade experience

13. Chiu YM, Lang HC*, Lin HY, Yang MT, Fang CH, Yan YW, Schabert VF, Tang B. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014 Dec;17 Suppl 3:9-19.

14. Cheng JS, Tsai WC, Lin CL, Chen L, Lang HC, Hsieh HM, Shin SJ, Chen T, Huang CT, Hsu CC. Trend and factors associated with healthcare use and costs in type 2 diabetes mellitus: A decade experience of a universal health insurance program. Med Care. 2015 Feb;53(2):116-24.

15. Chiu YM, Lai MS, Lin HY, Lang HC, Lee LJ, Wang JD. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):898-903

16. Chen HY, Chang HR, Lang HC*. Effects of Generic Drug substitution on Diabetes Therapy. Patient Prefer Adherence. 2014 Jan 29;8:127-33.

17. Shih CL, Chen CH, Sheu CF, Lang HC*, Hsieh CL. Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. Value Health. 2013 Jul-Aug;16(5):848-54.

18. Lang HC, Chang K, Ying YH*. Quality of Life, Treatment, and Patient Willingness to Pay for a Cure for Cervical Cancer in Taiwan. Health Econ. 2012 Oct;21(10):1217-33. (SCI). (Impact factor: 1.946;Rank: 12.13%)

19. Lang HC*, Wu SL. Lifetime Costs of the Top Five Cancers in Taiwan. Eur J Health Econ. 2012 Jun;13(3):347-53. (SCI). (Impact factor: 1.755;Rank: 15.41%)

20. Lang HC*. Willingness to Pay for Lung Cancer Treatment. Value in Health 2010; 13(6):743-9. ). (SCI). (Impact factor: 2.342;Rank: 8.85%)

21. Lang HC*, Scheffler RM, Hu TW. The Discrepancy in Attention Deficit Hyperactivity Disorder (ADHD) Medications Diffusion: 1994-2003-A global pharmaceutical data analysis. Health Policy 2010;97:71-78. (SCI).(Impact factor: 1.383;Rank: 51.72%)

22. Lu CL, Lang HC, Luo JC, Liu CC, Lin HC, Chang FY, Lee SD. Increasing Trend of the Incidence of Esophageal Squamous Cell Carcinoma, but not Adenocarcinoma, in Taiwan. Cancer Causes and Control. 2010;21(2):269-74. (SCI). (Impact factor: 2.789;Rank: 22.54%)

○ Publications in PubMed